Image source: Getty Images.
Continue Reading Below
Endo International (NASDAQ: ENDP) is up 15% at 3:17 p.m. EDT after the drugmaker announced that Paul Campanelli is taking over as president and CEO.
Campanelli, who was previously the president of Par Pharmaceuticals -- Endo's generic and OTC drugs business -- takes over for Rajiv De Silva. Campanelli was CEO of Par Pharmaceuticals before Endo acquired the company, so he has experience at the top.
Of course, this isn't so much an endorsement of Campanelli as a sign that investors weren't happy with the performance of Endo under De Silva's leadership. Shares are down 69% over the last year.
In addition to announcing the leadership change, Endo also reaffirmed its guidance of third quarter revenues between $830 million and $870 million and adjusted earnings between $0.77 and $0.82 per share. With just seven days left in the quarter, Endo should have a good idea where the top and bottom lines of the earnings report will fall. The company also reaffirmed its full-year guidance.
While meeting guidance is always nice, keep in mind that management lowered the bar in May, cutting full-year revenue guidance by 11% from its former high-end guidance and adjusted earnings per share guidance by 23%.
Campanelli isn't going to be able to turn Endo around overnight, but it seems reasonable that the shakeup makes the company worth a little more today.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.